sevabertinib (Hyrnuo)

Indications

• treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations

Contraindications

• pregnancy

Dosage

• 20 mg orally twice daily with food (Swallow tablets whole)
• sevabertinib 10 MG Oral Tablet (Hyrnuo)

Adverse effects

• > 20%
  • diarrhea. rash, paronychia, stomatitis, nausea
• laboratory:
  • hypokalemia, hyponatremia, lymphopenia, increased serum ALT & serum AST
  • increased serum lipase, increased serum amylase
• ocular toxicity
• hepatotoxicity

Mechanism of action

• reversible kinase inhibitor of human epidermal growth factor receptor 2 (HER2)
• also inhibits activity of epidermal growth factor receptor (EGFR).

More general terms

• small inhibitory antineoplastic agent (ib drug)

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=155234713